📈 Fed's first cut since 2020: Time to buy the dip? See Tech-focused stock picksUnlock AI Picks

Shire's CMV candidate maribavir successful in mid-stage study

Published 10/27/2016, 12:16 PM
Shire's CMV candidate maribavir successful in mid-stage study
  • Results from a Phase 2 clinical trial assessing Shire plc's in CMV-negative HSCT patients and SHP620-303 which will compare maribavir to investigator's choice of anti-CMV therapy in transplant patients with resistant/refractory CMV infection.
  • Treatment-resistant CMV infection is a substantial problem in transplant patients and is associated with significant complications and high mortality.
  • Maribavir is an antiviral drug called a benzimidazole riboside. It is believed to fight CMV by inhibiting DNA assembly and the escape of viral capsids from the nuclei of infected cells. It was originally developed by ViroPharma which Shire acquired in November 2013.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.